{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.24 vs. cons $1.09",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$47.85B vs. cons $47.64B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Consolidated health benefits ratio",
      "prediction": "IN-LINE",
      "answer": "pred ~90.9% vs. cons 91.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted diluted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide >$3.75 vs. cons $3.46 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Marketplace pretax margin",
      "prediction": "BETTER",
      "answer": "guide ~3.8% vs. cons 3.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Consolidated health benefits ratio",
      "prediction": "BETTER",
      "answer": "guide ~91.0% vs. cons 91.3% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 4.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 5.8,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Marketplace risk-adjustment validation and a higher FY2026 EPS floor should lift 2026 estimates from ~$3.46 toward ~$3.75 and support 2027 revisions from roughly $4.45 toward ~$4.70, producing follow-through after the initial beat.",
  "day5_confidence": "MEDIUM"
}